In the present study, we investigated whether a novel benzopyranylindol analogue,
KR-31466 (KR466) (1-[(2S,3R,4S)-3,4-dihydro-2-dimethoxymethyl-3-hydroxy-2-methyl-6-nitro-2H-1-
benzopyran-4-yl]-1H-
indole-2-
carboxylic acid ethyl
ester) can attenuate hypoxic injury in heart-derived H9c2 cells and, if so, whether the protective effect of KR466 is mediated through mitochondrial
ATP-sensitive
potassium (mtK(
ATP)) opening. The treatment of H9c2 cells with KR466 (3 - 30 microM) significantly reduced
hypoxia-induced cell death in a concentration-dependent manner, as shown by
lactate dehydrogenase release and
propidium iodide-uptake. In addition, KR466 (10 microM) significantly reduced the increase in
hypoxia-induced TUNEL-positive cells, suggesting its anti-apoptotic potential in H9c2 cells. The protective effects of KR466 were abolished by
5-hydroxydecanoate, a specific blocker of the mtK(
ATP) channel, suggesting the involvement of the mtK(
ATP) channel in the protective effect of KR466. A specific inhibitor of
protein kinase C (PKC),
chelerythrine (3 microM), significantly attenuated the protective effect of KR466 against
hypoxia-induced cardiac cell death. In conclusion, our results suggest that KR466 can protect H9c2 cells from
hypoxia-induced death through mtK(
ATP) channel opening and PKC activation.